Sugammadex information

Sugammadex
Clinical data
Pronunciation	soo GAM ma dex
Trade names	Bridion
Other names	ORG-25969
AHFS/Drugs.com	Monograph
License data	US DailyMed: Sugammadex;
Pregnancy; category	AU: B2; ;
Routes of; administration	Intravenous
ATC code	V03AB35 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	343306-71-8 ;
PubChem CID	6918585; as salt: 6918584;
DrugBank	DB06206 ;
ChemSpider	32689915 ;
UNII	361LPM2T56; as salt: ERJ6X2MXV7 ;
KEGG	as salt: D05940 ;
ChEBI	CHEBI:90953 ; as salt: CHEBI:90952 ;
ChEMBL	ChEMBL2111107; as salt: ChEMBL2107374;
ECHA InfoCard	100.121.931
Chemical and physical data
Formula	C72H112O48S8
Molar mass	2002.12 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O;
	InChI InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1 ; Key:WHRODDIHRRDWEW-VTHZAVIASA-N ;
	(what is this?) (verify)

Sugammadex, sold under the brand name Bridion, is a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium^[5] in general anaesthesia. It is the first selective relaxant binding agent (SRBA). It is marketed by Merck.^[8]

The most common side effects include cough, airway problems due to the anaesthesia wearing off, reduced blood pressure and other complications such as changes in heart rate.^[6]

Sugammadex is available as a generic medication.^[9]

^ SUGAMMADEX ACCORD (Accord Healthcare Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023
^ SUGAMMADEX SANDOZ (Sandoz Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023
^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ "Bridion 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 18 March 2021. Archived from the original on 27 June 2021. Retrieved 27 June 2021.
^ ^a ^b Cite error: The named reference Bridion FDA label was invoked but never defined (see the help page).
^ ^a ^b "Bridion EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Sugammadex Adroiq". Union Register of medicinal products. 30 May 2023. Retrieved 6 June 2023.
^ "Dosing for Bridion (sugammadex)". www.merckconnect.com. Archived from the original on 2019-01-12. Retrieved 2019-01-11.
^ "Sugammadex Adroiq". European Medicines Agency. 16 June 2023. Retrieved 19 June 2023.

[1] SUGAMMADEX ACCORD (Accord Healthcare Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023

[2] SUGAMMADEX SANDOZ (Sandoz Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023

[3] "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

[Bridion_SmPC-4] "Bridion 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 18 March 2021. Archived from the original on 27 June 2021. Retrieved 27 June 2021.

[Bridion_FDA_label-5] Cite error: The named reference Bridion FDA label was invoked but never defined (see the help page).

[Bridion_EPAR-6] "Bridion EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[7] "Sugammadex Adroiq". Union Register of medicinal products. 30 May 2023. Retrieved 6 June 2023.

[8] "Dosing for Bridion (sugammadex)". www.merckconnect.com. Archived from the original on 2019-01-12. Retrieved 2019-01-11.

[9] "Sugammadex Adroiq". European Medicines Agency. 16 June 2023. Retrieved 19 June 2023.

Sugammadex information

and 11 Related for: Sugammadex information

Sugammadex

Rocuronium bromide

Vecuronium bromide

Rapid sequence induction

Selective relaxant binding agents

Anesthetic

General anaesthesia

Postoperative residual curarization

ATC code V03

Fred Hassan

Newhouse Research Site